Some interventions that lower LDL cholesterol failed to reduce cardiovascular events
Assessment
The claim traces to reliable primary sources through a clear chain of evidence.
As an existential statement, this claim requires only that at least one LDL-lowering intervention have failed to reduce cardiovascular events in a well-conducted trial, and several clear examples exist. Adding niacin to statin therapy did not reduce major vascular events in the AIM-HIGH and HPS2-THRIVE trials despite further lowering LDL cholesterol. The CETP inhibitors torcetrapib, dalcetrapib, and evacetrapib all substantially altered lipid levels yet failed to reduce events, and torcetrapib actually increased cardiovascular events and total mortality (leading to early termination of its trial). The claim is therefore well established as a factual matter.
Its significance is more contested than its truth. These failures are commonly cited in debates over the cholesterol hypothesis, but the mainstream reconciliation is that each failure has a specific explanation that does not undercut LDL causality: torcetrapib had off-target harms (raised blood pressure and aldosterone), niacin added little LDL lowering on top of already well-controlled statin-treated patients, and the CETP agents' modest or offset LDL effects came with their own limitations. A later CETP inhibitor, anacetrapib, did modestly reduce events. So the existence of failed interventions is not itself evidence that lowering LDL fails to help; the interpretive weight of these cases is what the surrounding claims dispute.
Full reasoning — evidence and decisions behind this verdict
The claim is existential, so a single credible instance suffices and the three attached supporting subclaims each supply one: niacin-plus-statin (493a8e00), torcetrapib (e6524219), and CETP inhibitors generally (3304336c). Direct evidence confirms each. HPS2-THRIVE found niacin-laropiprant added to statin-treated patients at LDL goal did not significantly reduce major vascular events (rate ratio ~0.96, P=0.29), and AIM-HIGH was stopped for lack of benefit; the ILLUMINATE trial found torcetrapib increased both cardiovascular events and all-cause mortality, terminating its development; and the evacetrapib (ACCELERATE) and dalcetrapib (dal-OUTCOMES) trials showed no reduction in major adverse cardiovascular events despite large lipid changes, making evacetrapib the third CETP failure of its kind. These are large randomized outcome trials (primary sources), so source weight is high and the existential claim is verified.
Materiality note for the surrounding graph: this claim is worded neutrally as a factual existence statement and does not by itself contradict "elevated LDL causes cardiovascular disease" (verified) or "lowering LDL reduces events proportionally to the reduction achieved" (verified). The standard explanations (off-target harm for torcetrapib, minimal incremental LDL lowering for niacin on background statin, modest/offset effects for CETP agents, and the later partial success of anacetrapib in REVEAL) reconcile the failures with LDL causality. The debate lives in those neighboring claims, not in the truth of this one.
What would change the verdict: retraction or major re-analysis overturning these trial results, which is not in prospect. Confidence in the verified status is high; a small reservation reflects only that a reader could dispute whether "failed to reduce" fairly characterizes borderline non-significant results (e.g., HPS2-THRIVE's point estimate).
Decomposition
The claims this one rests on directly. ↗︎ opens a subclaim; the map shows how they fit together.
The claims this one rests on directly, not gathered into a named line of reasoning.
- supportsthis provides evidence for the parentsteward instructions →CETP inhibitors substantially lowered LDL cholesterol but failed to reduce cardiovascular events ↗︎
- supportsthis provides evidence for the parentsteward instructions →Torcetrapib lowered LDL cholesterol but increased cardiovascular events and mortality ↗︎
- supportsthis provides evidence for the parentsteward instructions →Niacin added to statin therapy failed to reduce cardiovascular events ↗︎
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 19, 2026. Every judgment on this page is accompanied by a reasoning trace.